1.Preparedness for Zika virus testing in the World Health Organization Western Pacific Region
Raynal C Squires ; Frank Konings
Western Pacific Surveillance and Response 2016;7(1):44-47
On 1 February 2016, the World Health Organization (WHO) declared that clusters of microcephaly cases and other neurological disorders occurring in Zika virus (ZIKV)-affected areas constituted a public health emergency of international concern. Increased surveillance of the virus, including the requirement for laboratory confirmation of infection, was recommended. The WHO Regional Office for the Western Pacific therefore initiated a rapid survey among national-level public health laboratories in 19 countries and areas to determine regional capacity for ZIKV detection. The survey indicated that 16/19 (84%) countries had capacity for molecular detection of ZIKV while others facilitated testing through referral. These results suggest that robust laboratory capacity is in place to support ZIKV surveillance in the Western Pacific Region.
2.Preparedness for molecular testing of Middle East respiratory syndrome coronavirus among laboratories in the Western Pacific Region
Squires Raynal C ; Konings Frank
Western Pacific Surveillance and Response 2014;5(3):40-42
Since the notification of the first cases of Middle East respiratory syndrome coronavirus (MERS-CoV) in September 2012, a total of 837 laboratory-confirmed cases and 291 deaths have been reported globally as of 23 July 2014, primarily in the Arabian Peninsula. However, the possibility of importation of MERS-CoV in the World Health Organization (WHO) Western Pacific Region exists given the large number of individuals who travel annually to the Middle East for religious purposes, employment or other reasons.
3.Ebola preparedness in the Western Pacific Region, 2014
Zhen Xu ; Boris I Pavlin ; Raynal C Squires ; Thilaka Chinnayah ; Chin-Kei Lee ; Ailan Li
Western Pacific Surveillance and Response 2015;6(1):66-72
West Africa is currently experiencing the largest outbreak of Ebola virus disease (EVD) in history with intense transmission in several affected countries. For non-affected countries, the best protective measures are adequate levels of preparedness including vigilant surveillance to detect cases early and well-prepared health systems to ensure rapid containment of the virus and to avoid further spread. The World Health Organization Regional Office for the Western Pacific recently conducted two activities: a web-based EVD preparedness survey and an EVD simulation exercise to determine the overall level of EVD preparedness in the Region. The survey and exercise together demonstrate there is a good overall level of preparedness for a potential imported case of EVD in the Western Pacific Region. However, a number of areas still require further strengthening before the Region can efficiently and effectively respond to potential EVD events, including laboratory testing arrangements; clinical management and infection prevention and control; and public health intervention measures, particularly at points of entry. Importantly, the survey and exercise also highlight the unique situation in Pacific island countries and emphasize that special considerations are needed to better support these countries in EVD preparedness.
4.External quality assessment of dengue and chikungunya diagnostics in Asia Pacific region, 2015
Li Ting Soh ; Raynal C Squires ; Li Kiang Tan ; Kwoon Yong Pok ; HuiTing Yang ; Christina Liew ; Aparna Singh Shah ; John Aaskov ; Sazaly Abubakar ; Futoshi Hasabe ; Lee Ching Ng ; Frank Konings
Western Pacific Surveillance and Response 2016;7(2):26-34
OBJECTIVE: To conduct an external quality assessment (EQA) of dengue and chikungunya diagnostics among national-level public health laboratories in the Asia Pacific region following the first round of EQA for dengue diagnostics in 2013.
METHODS: Twenty-four national-level public health laboratories performed routine diagnostic assays on a proficiency testing panel consisting of two modules. Module A contained serum samples spiked with cultured dengue virus (DENV) or chikungunya virus (CHIKV) for the detection of nucleic acid and DENV non-structural protein 1 (NS1) antigen. Module B contained human serum samples for the detection of anti-DENV antibodies.
RESULTS: Among 20 laboratories testing Module A, 17 (85%) correctly detected DENV RNA by reverse transcription polymerase chain reaction (RT-PCR), 18 (90%) correctly determined serotype and 19 (95%) correctly identified CHIKV by RT-PCR. Ten of 15 (66.7%) laboratories performing NS1 antigen assays obtained the correct results. In Module B, 18/23 (78.3%) and 20/20 (100%) of laboratories correctly detected anti-DENV IgM and IgG, respectively. Detection of acute/recent DENV infection by both molecular (RT-PCR) and serological methods (IgM) was available in 19/24 (79.2%) participating laboratories.
DISCUSSION: Accurate laboratory testing is a critical component of dengue and chikungunya surveillance and control. This second round of EQA reveals good proficiency in molecular and serological diagnostics of these diseases in the Asia Pacific region. Further comprehensive diagnostic testing, including testing for Zika virus, should comprise future iterations of the EQA.
5.First round of external quality assessment of dengue diagnostics in the WHO Western Pacific Region, 2013
Pok Kwoon Yong ; Squires Raynal C ; Tan Li Kiang ; Takasaki Tomohiko ; Abubakar Sazaly ; Hasebe Futoshi ; Partridge Jeffrey ; Lee Chin Kei ; Lo Janice ; Aaskov John ; Ng Lee Ching ; Konings Frank
Western Pacific Surveillance and Response 2015;6(2):73-81
Objective:Accurate laboratory testing is a critical component of dengue surveillance and control. The objective of this programme was to assess dengue diagnostic proficiency among national-level public health laboratories in the World Health Organization (WHO) Western Pacific Region.Methods:Nineteen national-level public health laboratories performed routine dengue diagnostic assays on a proficiency testing panel consisting of two modules: one containing commercial serum samples spiked with cultured dengue viruses for the detection of nucleic acid and non-structural protein 1 (NS1) (Module A) and one containing human serum samples for the detection of anti-dengue virus antibodies (Module B). A review of logistics arrangements was also conducted.Results:All 16 laboratories testing Module A performed reverse transcriptase polymerase chain reaction (RT–PCR) for both RNA and serotype detection. Of these, 15 had correct results for RNA detection and all 16 correctly serotyped the viruses. All nine laboratories performing NS1 antigen detection obtained the correct results. Sixteen of the 18 laboratories using IgM assays in Module B obtained the correct results as did the 13 laboratories that performed IgG assays. Detection of ongoing/recent dengue virus infection by both molecular (RT–PCR) and serological methods (IgM) was available in 15/19 participating laboratories.Discussion:This first round of external quality assessment of dengue diagnostics was successfully conducted in national-level public health laboratories in the WHO Western Pacific Region, revealing good proficiency in both molecular and serological testing. Further comprehensive diagnostic testing for dengue virus and other priority pathogens in the Region will be assessed during future rounds.